PCVX - NASDAQ
Vaxcyte, Inc.
$46.93
-0.57%Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
At a Glance
Live SnapshotVaxcyte, Inc. Management Team
Ms. Whitney Jones
Chief People Officer
Mr. Harp Dhaliwal M.B.A.
Chief Technical Operations Officer
Compensation
$146,484
Dr. Jeff Fairman Ph.D.
Co-Founder & Vice President of Research
Mr. Grant E. Pickering M.B.A.
Co-Founder, Chief Executive Officer & Director
Compensation
$1,397,299
Mr. James Wassil M.B.A., M.S.
Executive Vice President & Chief Operating Officer
Compensation
$564,809
Mr. Andrew L. Guggenhime M.B.A.
President & Chief Financial Officer
Compensation
$987,799
Ms. Janet Graesser
Senior Vice President of Corporate Affairs
Ms. Janet Graesser
Senior Vice President of Corporate Communications & Investor Relations
Ms. Elvia Cowan
Senior Vice President of Finance
Mr. Paul W. Sauer M.B.A.
Senior Vice President of Process Development & Manufacturing
Compensation
$608,956
Sam Iki
Senior Vice President of Project Management
Mr. Mikhail Eydelman J.D.
Senior Vice President, General Counsel, Chief Compliance Officer & Corporate Secretary
Compensation
$813,774
Vaxcyte, Inc. Insider Positioning
During the last 12 months, insiders have sold $1.45M worth of PCVX shares, with no buying activity reported.
3 Months
0
0.00
13.1K
760.33K
-760K
-$760K
3-6 Months
0
0.00
14.7K
689.93K
-690K
-$690K
6-9 Months
0
0.00
0
0.00
+0
+$0
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Cowan Elvia
Officer: Svp, Finance & Cao
$644K
Dhaliwal Harpreet S.
Officer: Chief Technical Ops Officer
$455K
Wassil Jim
Officer: Chief Operating Officer
$351K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $1.45M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
PCVX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 15, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 28, 2025 | June 12, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 15, 2024 | June 06, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 28, 2023 | April 28, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 20, 2022 | June 01, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 14, 2021 | June 02, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.